Scarica l'app Stockscreener
1.24
5.08%
0.06
Dopo l'orario di chiusura:
1.17
-0.07
-5.65%
Precedente Chiudi:
$1.18
Aprire:
$1.18
Volume 24 ore:
296.05K
Relative Volume:
0.93
Capitalizzazione di mercato:
$67.23M
Reddito:
-
Utile/perdita netta:
$-151.16M
Rapporto P/E:
-0.4175
EPS:
-2.97
Flusso di cassa netto:
$-130.08M
1 W Prestazione:
+9.73%
1M Prestazione:
-13.89%
6M Prestazione:
+170.33%
1 anno Prestazione:
-32.97%
Intervallo 1D:
$1.18
$1.34
Intervallo di 1 settimana:
$1.07
$1.34
Portata 52W:
$0.404
$2.27
Alx Oncology Holdings Inc Stock (ALXO) Company Profile
Nome
Alx Oncology Holdings Inc
Settore
Industria
Telefono
650-466-7125
Indirizzo
323 ALLERTON AVENUE, SOUTH SAN FRANCISCO
Confronta ALXO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ALXO
Alx Oncology Holdings Inc
|
1.24 | 63.98M | 0 | -151.16M | -130.08M | -2.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.68 | 122.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
801.01 | 85.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
399.40 | 55.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
795.57 | 50.67B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
170.27 | 37.54B | 447.02M | -1.18B | -906.14M | -6.1812 |
Alx Oncology Holdings Inc Stock (ALXO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-13 | Iniziato | Jefferies | Buy |
| 2025-03-06 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-12-19 | Downgrade | Jefferies | Buy → Hold |
| 2024-03-08 | Downgrade | Stifel | Buy → Hold |
| 2023-12-08 | Aggiornamento | Jefferies | Hold → Buy |
| 2021-12-22 | Downgrade | Jefferies | Buy → Hold |
| 2021-09-30 | Iniziato | Stifel | Buy |
| 2021-05-05 | Ripresa | Credit Suisse | Outperform |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2021-04-06 | Iniziato | UBS | Buy |
| 2021-02-10 | Iniziato | H.C. Wainwright | Buy |
| 2020-08-11 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-08-11 | Iniziato | Credit Suisse | Outperform |
| 2020-08-11 | Iniziato | Jefferies | Buy |
| 2020-08-11 | Iniziato | Piper Sandler | Overweight |
Mostra tutto
Alx Oncology Holdings Inc Borsa (ALXO) Ultime notizie
Why ALX Oncology Holdings Inc. stock remains undervaluedWeekly Market Report & Daily Momentum Trading Reports - ulpravda.ru
How ALX Oncology Holdings Inc. stock compares to market leadersJuly 2025 Momentum & Safe Capital Growth Stock Tips - ulpravda.ru
How geopolitical tensions affect ALX Oncology Holdings Inc. stock2025 Macro Impact & Verified Trade Idea Suggestions - ulpravda.ru
ALX Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference - Chartmill
ALX Oncology Advances Separate Clinical Trials Evaluating Investigational CD47-Inhibitor Evorpacept and Novel EGFR-Targeted Antibody-Drug Conjugate ALX2004 - Yahoo Finance
After-Hours Gainers: ALXO, GMED, ACRV, And Biotech Peers Rally On Trial Data And Earnings Updates - RTTNews
Meme Stocks: Will ALX Oncology Holdings Inc stock deliver consistent dividends2025 Valuation Update & Weekly Market Pulse Updates - moha.gov.vn
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Given Average Rating of “Moderate Buy” by Brokerages - Defense World
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Short Interest in ALX Oncology Holdings Inc. (NASDAQ:ALXO) Expands By 32.0% - Defense World
ALXOAmended Statement of Beneficial Ownership (3/a) - ADVFN
ALX Oncology Reports Third Quarter 2020 Financial Results and Provides Clinical Development and Operational Highlights - ADVFN
ALX Oncology Reports Second Quarter 2024 Financial Results and Provides Corporate Update - ADVFN
ALX Oncology (NASDAQ:ALXO) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Aug PostEarnings: What technical charts say about ALX Oncology Holdings Inc. stock2025 Market WrapUp & Free Expert Verified Stock Movement Alerts - DonanımHaber
What momentum indicators show for ALX Oncology Holdings Inc. stockMarket Risk Summary & AI Driven Price Forecasts - Улправда
Alx Oncology: A Study in Contrasting Market Sentiment - AD HOC NEWS
ALX Oncology (NASDAQ:ALXO) Lowered to “Sell” Rating by Wall Street Zen - Defense World
ALX Oncology (NASDAQ:ALXO) Lowered to "Sell" Rating by Wall Street Zen - MarketBeat
Alx Oncology rallies on strong phase 2 data for lymphoma therapy - MSN
Alx Oncology stock soars after impressive lymphoma treatment results By Investing.com - Investing.com UK
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
ALX Oncology (Nasdaq:ALXO) Reports High Response Rates for Evorpacept Combo in Indolent B-cell NHL at ASH 2025 - Kalkine Media
ALXO: Promising Phase 2 Trial Results for Evorpacept in iNHL Tre - GuruFocus
Alx Oncology Holdings Inc. Announces Positive Results from Ongoing Investigator-Sponsored Phase 2 Trial Evaluating Evorpacept in Combination with Standard-Of-Care Treatment in Patients with Indolent B-Cell Non-Hodgkin Lymphoma, At Ashodgkinlymph - marketscreener.com
ALX Oncology Announces Positive Results from Ongoing Investigator-Sponsored Phase 2 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with Indolent B-cell Non-Hodgkin Lymphoma, at ASH Annual Meeting - Sahm
ALX Oncology (NASDAQ:ALXO) Upgraded by Wall Street Zen to Hold Rating - MarketBeat
ALX Oncology (NASDAQ:ALXO) Stock Price Up 3.8%Here's Why - MarketBeat
Reviewing Harmony Biosciences (NASDAQ:HRMY) and ALX Oncology (NASDAQ:ALXO) - Defense World
Why ALX Oncology Holdings Inc. stock could benefit from AI revolutionMarket Growth Summary & High Accuracy Trade Signal Alerts - Newser
HER2-positive Gastric Cancer Clinical Trial Pipeline: Insights into a Growing Landscape with 20+ Companies Advancing Novel Treatments| DelveInsight - GlobeNewswire
How resilient is ALX Oncology Holdings Inc. stock in market downturnsMarket Trend Summary & Consistent Profit Trade Alerts - newser.com
Jefferies reiterates Buy rating on ALX Oncology stock, sees potential in cancer programs - Investing.com Canada
Can ALX Oncology Holdings Inc. hit a new high this month2025 Volatility Report & Daily Profit Maximizing Tips - newser.com
What analyst consensus says on ALX Oncology Holdings Inc. stockQuarterly Profit Summary & Consistent Growth Stock Picks - newser.com
Will ALX Oncology Holdings Inc. stock outperform Dow Jones index2025 Fundamental Recap & Accurate Entry/Exit Alerts - newser.com
Is ALX Oncology Holdings Inc. stock attractive for long term wealth buildingVolume Spike & Expert Curated Trade Setups - newser.com
Is ALX Oncology Holdings Inc. stock attractive for hedge fundsEntry Point & Consistent Growth Equity Picks - newser.com
Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B - Markets Financial Content
ALXO: Two high-value oncology programs advance toward key 2025 data with strong financial support - TradingView
Published on: 2025-11-19 06:30:37 - newser.com
Published on: 2025-11-19 06:25:55 - newser.com
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Fate Therapeutics (FATE), ALX Oncology Holdings (ALXO) and 60 Degrees Pharmaceuticals, Inc. (SXTP) - The Globe and Mail
Will ALX Oncology Holdings Inc. stock deliver long term returnsCEO Change & Entry Point Confirmation Signals - newser.com
Published on: 2025-11-18 23:37:11 - newser.com
Alx Oncology Holdings Inc Azioni (ALXO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.80%
4.56%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):